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ABSTRACT OF THE THESIS
THE EFFECT OF TOTAL PARENTERAL NUTRITION (TPN) ON
ZINC (Zn) RETENTION IN THE TISSUES OF RATS
by
Martha M. Chisholm
Florida International University, 1995
Miami, Florida
Professor Evelyn B. Enrione, Major Professor
Zn is regularly added to TPN solutions, however, requirements
are poorly understood. This research investigated whether or
not the route of Zn intake (oral vs parenteral) changes Zn
concentration in rat tissues. Twenty-four male Fischer-344
rats were equally and randomly assigned to one of four groups
(n=6): control (CON), baseline (BS), orally fed (OF), and
intravenously fed (IV). After fifteen days of feeding, organs
and sera were collected and analyzed for Zn by atomic
absorption spectrophotometry. Of the nine tissues analyzed,
the Zn concentrations in the liver, kidney, and lung of the IV
rats were significantly higher (p<1.l) than those of the CON,
BS, and OF rats. Results indicated that rats fed
intravenously with Zn displayed increased Zn concentrations in
liver, kidney and lung tissues, and that the concentration of
Zn in the serum may not reflect tissue Zn levels. This
suggests that the route of Zn intake affects tissue Zn
concentration.
v
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Introduction
Zinc (Zn) nutriture is recognized as being important not
only for the healthy population but also for the acutely and
chronically ill patient experiencing and/or recovering from a
variety of medical conditions, especially those necessitating
total parenteral nutrition (TPN) (1, 2, 3, 4, 5, 6,7,8, 9,10,11,12).
Although trace elements, including Zn, are regularly added to
TPN solutions, requirements are poorly understood. This is
due to the lack of sufficient animal and human data which
would support specific recommendations for Zn requirements in
TPN solutions, and to the wide range of medical diseases which
alter Zn requirements and require TPN (2).
Despite the 1979 guidelines set forth by the American
Medical Association on parenteral trace element administration
(13), suboptimal body Zn nutriture continues to be a risk in
patients receiving TPN for long periods of time. In the
United States, studies which evaluate the effect of TPN on
trace element retention in body tissues have not been
completed. Few foreign studies have been conducted to
investigate changes in tissue Zn nutriture during TPN; these
have been limited by availability of tissues for analyses
(14), or have used a variety of Zn dosages unrelated to the
daily Zn requirement for rats (15,16) . It was apparent that
studies were needed to evaluate the effects of intravenous Zn
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administration on tissue Zn retention, and to compare these
results to the effect which normal oral Zn intake has on
tissue Zn homeostasis. Previously, it was not clear how the
oral Zn requirement for rats related to the intravenously
administered requirement nor how this might change tissue Zn
concentration in specific organs. Therefore, this study was
developed to determine if the route of Zn intake (oral vs
parenteral) changes Zn retention in rat tissues.
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Review of Literature
Zn Nutriture with TPN Solutions
Historical Review
Zn deficiency was not diagnosed during the initial years
of parenteral nutrition because infusions could only be
administered for a few days (17,18,19). In the early 1960's
and 1970's, technical problems with hyperosmolar parenteral
nutrition solutions continued (17), preventing long-term
administration of the solutions. This preceded administration
of solutions through deep venous catheters (17,20,21,22),
which allowed longer parenteral nutrition infusions without
complications. There was no immediate concern about Zn
deficiency in patients, although reference to possible risk of
Zn deficiency was made (18,23).
Originally, the nitrogen components of the solution were
protein hydrolysates which were naturally contaminated with
trace elements (23,24). This contamination made Zn deficiency
relatively rare for early TPN patients (24). However, these
solutions contained protein hydrolysates and dextrose that
were heat sterilized (2). This heat sterilization process
formed sugar-amino acid complexes (2). These complexes bound
Zn and formed metal-sugar-amino acid complexes that resulted
in excessive loss of Zn in the urine and increased Zn
deficiency risk due to the inability to retain Zn
appropriately in the body (2).
In the mid to late 1970's, the protein source in TPN
solutions changed from protein hydrolysates to crystalline
amino acids, containing only L-amino acids. Because the
solutions no longer required heat sterilization (2,17), the
metal-sugar-amino acid complexes did not form and thus urinary
Zn loss was prevented (2), Conversely, it is documented that
infants fed parenterally lose Zn predominately through the
urine (rather than through the stool, as in orally-fed
infants) (2,12,24,25).
The use of crystalline amin9 acids without Zn
supplementation was an important factor in producing Zn
deficiency in adult patients receiving TPN. Highly purified
intravenous solutions, with minimal Zn contamination, were
related to an increased risk of Zn deficiency, as was the
concurrent altered plasma concentration of certain amino
acids. The Zn-binding amino acid, histidine, increased the
risk of renal Zn ultrafilterability, and along with cysteine,
promoted increased urinary excretion of Zn in animals and
humans (25,26,27). In 1977, Freeman and Taylor showed how the
administration of histidine, either orally or intravenously,
significantly increased (three to six times) urinary excretion
of Zn in rats, when compared to controls (27). However, no
clinical evidence of Zn deficiency was found after histidine
was administered for 43 days (27).
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Nevertheless, by the late 1970's, because of the change
to crystalline amino acids, and the experiences with Zn
deficiency, it became apparent that formal recommendations
were needed for Zn supplementation in TPN (12,13).
Zn Supplementation Recommendations
In 1979, the Nutrition Advisory Group of the Department
of Foods and Nutrition, American Medical Association (AMA)
directed an expert panel to set guidelines for essential trace
element preparations for parenteral use (13). The AMA expert
panel modified the essential human dietary Zn requirements
(attained via balance studies, intestinal absorption and
excretory route studies), in order to develop guidelines for
intravenous Zn intake (13). They considered that the daily
dietary oral requirement for Zn was 10.1-11.5 mg/day, the
intestinal absorption factor was 10-40% (factors such as
phytate, fiber, calcium, and protein content of a meal could
affect Zn absorption), and the absolute daily oral requirement
for Zn was 2.5 mg/day when absorption losses were eliminated
(13).
Suggested daily intravenous Zn intake was 2.5-4.0 mg for
the stable adult and an additional 2.0 mg for adults in acute
catabolic states. For a stable adult with intestinal losses,
an additional 12.2 mg of Zn/liter of small-bowel fluid lost
was recommended, or 17.1 mg of Zn/kg of stool or ileostomy
losses. The panel stressed the need for frequent monitoring
of blood levels in these patients to provide proper dosage
(13).
In 1988, the Subcommittee on Pediatric Parenteral
Nutrient Requirements from the Committee on Clinical Practice
Issues of The American Society for Clinical Nutrition (ASCN)
published an update and extension of the 1979 statement by the
AMA expert panel (12) . The Committee of the ASCN stressed the
need to add Zn to TPN solutions for pediatric patients, even
for supplemental or short-term (less than four weeks)
parenteral support, since deficiency symptoms could develop
quickly if Zn status was poor or when there were significant
Zn losses (12). Daily intravenous recommendations for the
pediatric population were: 1) 400 pg/kg for premature infants
weighing less than 1500 grams and up to 3 kg, 2) 250 pg/kg for
full term infants less than 3 months old, and 3) 100 pg/kg for
full term infants older than 3 months and 50 pg/kg (maximum
5000 pg/day) for children up to 5 years old (12,13). After 5
years of age, the recommendations of intravenous Zn
supplementation for adults applied (13).
However, even with these recommendations, Zn deficiency
and/or negative Zn balance continued to be documented in
adults and children (1,8,9,10,11,12,28). A simple diagnostic
test such as serum Zn concentration was not reflective of body
tissue Zn status (14, 29, 30 , 31, 35) . Therefore, there was a
need to investigate the effects of parenteral Zn
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administration and subsequent Zn concentration in body tissues
in order to add to the data about the Zn requirement necessary
to maintain Zn balance and homeostasis during intravenous
nutrition support.
Tissue Retention of Zn with TPN Administration
Only one study from Finland evaluated tissue retention of
Zn from Zn administered intravenously during TPN in humans
(14). Twenty-four malnourished surgical patients received one
of three different parenteral nutrition regimens, consisting
of total kilocalories predominantly as glucose, lipid or a
high amino acid (3 g AA/kg/day) solution. Liver and muscle
were biopsied for Zn and serum was collected (14).
The Zn concentration decreased in the liver and serum
regardless of the nutrition regimen (14). No changes in Zn
concentration were seen in muscle. Daily urinary Zn excretion
increased in eight patients, and the amount of daily
intravenous Zn the patients received was approximately that
excreted in their urine (14). Tulikoura and Vuori concluded
that daily supplementation of 1.9 mg of Zn in the parenteral
solution was inadequate, and that at least 5 mg of Zn daily
was necessary in their patients, if not more, and that these
recommendations were in accordance with the 1979 AMA
guidelines (13,14).
Tulikoura and Vuori's human study had several factors
which may have affected their results. First, the parenteral
solutions they used were not proportionately correct in
reference to recommended macronutrient distribution.
Kilocalorie intake was not equivalent among the groups and
protein intake was either too low or too high (14). High
protein intake has been previously documented to affect Zn
metabolism (32,33). Also since it was a human study,
limitations were expected on the variety of tissues available
for Zn analysis.
Although one human study demonstrated changes in tissue
Zn homeostasis, most of the information regarding tissue
retention of intravenously administered Zn has come from
animal studies, specifically the rat. Several foreign studies
investigated the effect of Zn in TPN solutions on Zn retention
in rat tissues.
Poriadkov et al. studied rats that received complete
intravenous nutrition for fifteen days and found growth of the
liver during parenteral nutrition followed by an increase in
Zn content in whole liver tissue (34). Yokoi et al. studied
six week-old, Sprague-Dawley male rats (160-180 g) that were
orally fed a trace element-deficient diet for two weeks (15).
There were three groups nourished for one week as follows:
Group A - TPN without trace element supplementation
(approximately 11 pg/kg body weight/day) ; Group B - TPN
supplemented with trace elements including zinc (approximately
8
1312 pg/kg body weight/day); and Group C - an oral diet
without trace elements (14.2 mg Zn/kg diet). A control group
(Group D) was fed an oral diet for three weeks supplemented
with trace elements (55.3 mg Zn/kg diet). The Zn
concentration in the plasma and liver of Group B was higher
than that of Group C (15). Heart, kidney, testis, muscle, and
tibia Zn concentrations remained constant between these two
groups (15). In general, plasma and tissue Zn concentrations
decreased during TPN without Zn, and this effect was prevented
by Zn supplementation in the TPN solution (15).
Matsuda et al, studied four groups of five-week old,
Sprague-Dawley male rats (180-210 g) (16). All were allowed
an acclimation period of one week prior to undergoing surgical
placement of a central catheter into the superior vena cava.
Treatments consisted of either an oral diet or TPN for one
week as follows: Group A - a Control group fed a synthetic
normal diet (approximately 34.43 mg Zn/kg diet); Group B -
received TPN without trace element supplementation; Group C -
had infused TPN supplemented with trace elements including Zn
(approximately 101 pg/kg body weight/day); and Group D -
received TPN supplemented with three times the dose of Zn
(approximately 302 pg/kg body weight/day), Groups B, C, and
D received lower daily intravenous Zn infusions when compared
to that received in a standard oral rat diet. The Zn
concentration in the brain, heart, kidney, tibia, plasma, and
whole blood decreased in Group B compared to control Group A
(16). The higher the supplemental Zn received by Groups B, C,
and D respectively, the higher the Zn concentration in the
tissues (16). This was seen most significantly in the plasma
Zn concentration, where Groups B, C, and D were different from
each other and Groups B and C had significantly lower Zn
concentration compared to control Group A (16). Also for
kidney, the Zn concentration of control Group A was higher
than for Groups B, C, and D (16). The authors found no
difference in Zn concentration in liver, femoral muscle,
testis, and spleen among the groups (16). However, since the
Zn concentrations fell in plasma and kidney, it was not
conclusive as to whether the Zn infusion in the TPN solution
of Groups C or D was adequate or inadequate to maintain tissue
Zn homeostasis, However, it was evident that dosage of
intravenous Zn plays a major role in certain tissue Zn
concentrations.
Yamato investigated the concentration of Zn in the serum
and organs of male Wistar rats (200 to 250 g) during TPN,
while they received solutions containing different
concentrations of Zn (35). The rats were divided into four
groups. Group A rats were fed orally a diet containing 60
mg/kg of Zn. Groups B, C, and D received TPN for one week.
Zinc from Zn sulfate was infused as follows: Group B received
TPN without added trace elements; Group C received
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approximately 80 yg Zn/kg body weight/day; Group D received
approximately 4440 Mg Zn/kg body weight/day. In Group D, the
author found the Zn concentration increased in the liver,
kidney, small intestine, serum, muscle, and thigh bone, (as
well as in pancreas, skin, brain, and cecum) compared to
control Group A (35). In Groups B and C, the Zn concentration
decreased in the small intestine (it also decreased in the
serum in Group B), compared to control Group A; however, the
Zn concentration increased in their muscle and thigh bone
(reasons for this increase were not discussed in Yamato's
study) (35). The Zn concentrations in all other tissues in
Groups B and C were not significantly different from those in
Group A (35), Yamato has shown that about 80 Mg/kg body
weight/day of intravenous Zn could maintain normal Zn tissue
concentrations in rats not losing gastrointestinal fluids, and
that 180 Mg/kg body weight/day of intravenous Zn was necessary
to maintain positive Zn balance in rats with abnormal
pancreatic and bile loss (35). However, Matsuda et al. (16)
have shown that intravenous Zn infusions of 101 and 302 Mg
Zn/kg body weight/day produced lower plasma and kidney Zn
concentrations compared to controls consuming an oral diet
(even when considering that oral diet contained three times
the dietary Zn requirement for rats) . Therefore, Yamato's
results were not conclusive as to whether the Zn infusion in
the TPN solution of Group C (80 pg Zn/kg body weight/day) was
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adequate or inadequate to maintain tissue Zn homeostasis,
although it seemed that 4440 Mg Zn/kg/day was excessive and
disrupted tissue Zn balance (35).
Matsuda et al. investigated the effects of intravenous
injection of a trace element supplement on zinc concentrations
in tissue and plasma of rats (mean weight 240 g) (36). After
a one week acclimation period, eating a normal diet, the rats
were treated for seven days by intravenous injection of a
trace element preparation containing Zn as follows: Group 1 -
approximately 78 g Zn/kg body weight/day; Group 2 -
approximately 784 pg Zn/kg body weight/day; Group 3 -
approximately 2352 pg Zn/kg body weight/day; and Group 4 -
approximately 7840 Mg Zn/kg body weight/day. The authors
found that neither 78 pg Zn/kg/day nor 784 pg Zn/kg/day
affected the zinc concentrations in tissues, except a
significantly higher plasma Zn concentration with 784 Mg
Zn/kg/day compared to controls and those receiving the lesser
amount (36). After receiving the larger dose of 2352 Mg
Zn/kg/day, Zn concentrations in the liver, kidney, tibia and
plasma of the rats increased significantly compared to
controls (36). With the largest dose of 7840 pg Zn/kg/day,
all the rats died, and Zn concentrations in their tissues
increased tremendously compared to controls (36). The authors
suggested that Zn concentrations in tissues and plasma were
appropriately maintained, compared to controls, with doses up
12
to approximately 784 pg Zn/kg/day, but that doses higher than
that would likely unbalance Zn homeostasis (36). This data
also supported the importance of intravenous Zn dosage on
tissue Zn concentrations and homeostasis, although difference
of a single one-time daily administration dose versus a 24-
hour continuous administration dose in TPN needed to be
considered.
In summary, differences found in various rat studies
evaluating the effects of intravenous Zn infusions on tissue
Zn retention were: 1) control rats which underwent a surgical
procedure to receive a central venous catheter had an added
variable that may have affected Zn metabolism and homeostasis,
2) control rats often received oral diets with higher Zn
content than that required, 3) results were not conclusive as
to the quantity of intravenous Zn which maintained tissue Zn
homeostasis, and 4) intravenous Zn infusion was not always
evaluated in the context of TPN. Therefore, collection of
additional data was indicated to evaluate how Zn in TPN
affects body tissue Zn status compared to Zn consumed from a
standard oral diet.
13
Methodology
Animal Management and Experimental Design
Twenty-f our male Fischer-344 rats (Harlan Sprague-Dawley,
Indianapolis, IN) weighing 140 to 160 grams (g) were housed
individually in stainless steel metabolic cages containing
wire-mesh bottoms, in an environmentally controlled room with
12-hour light and dark cycles. During the experimental
period, the temperature ranged from 18*C to 260 C and the
relative humidity ranged from 40% to 70%.
The animals had free access to an amino acid diet (AAD)
and distilled and deionized (DDI) (Mega-Pure, Barnstead Co.,
Dubuque, IA) water during an acclimation period of eight days
(Figure 1). Food consumption and body weights were recorded
every three days. Rats were equally and randomly assigned to
one of four groups (n=6): a control group (CON), baseline
group (BS), an intravenously fed group (IV), and an orally fed
group (OF).
On day nine of the experiment, all rats (except the CON
group) were anesthetized, and had a catheter surgically placed
into the superior vena cava. During a recovery period of four
days, all the rats were allowed ad libitum access to the AAD
and DDI water. On day thirteen of the experiment, the rats in
the BS group were anesthetized, exsanguinated and eviscerated
in order to determine baseline tissue values.
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Figure 1. Experimental Design of Animal Management
and Nutritional Protocol
Day CON (n=6) BS (n=6) OF (n=6) IV (N=6)
1 Rats Rats Rats Rats
I I I IAAD & AAD & AAD & AAD &
Water Water Water Water
ad lib ad lib ad lib ad lib
9 Surgery Surgery Surgery
I I I
AAD & AAD & AAD &
Water Water Water
ad lib ad lib ad lib
I I
13 Killed TPN
Initiated
TPN;
Water
ad lib
28 Killed Killed Killed
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Total parenteral nutrition was initiated in the IV rats,
while the CON and OF rats continued to consume the AAD. All
rats continued to have ad libitum access to DDI water. The
rats were fed for 15 additional days with food intake and body
weights recorded every third day for the entire experimental
period. Feces and urine were also collected at that time. On
day twenty-eight of the experiment, all rats were killed in a
manner similar to that of the BS group.
The rats were cared for according to the Guide for the
Care and Use of Laboratory Animals (37) and the experiment was
approved by the Institutional Animal Care and Use Committee of
Florida International University.
Surgical Catheter Placement
A catheter was surgically placed into the superior vena
cava of all rats (except the CON group) by aseptic technique,
according to the methods of Enrione et al. and Popp et al.
(Appendix A) (38,39). The rats were anesthetized with an
intraperitoneal injection of sodium pentobarbital (30 mg/kg
body weight). After cleansing the ventral neck, mid-scapular
and suprascapular areas, a 3 cm incision was extended from
above the suprasternal notch up the ventral neck of the rat.
The right external jugular was dissected free and a small
incision was made in it. The beveled end of a silicone rubber
catheter (Silastic, Dow Corning Co., Midland, MI) was threaded
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2 cm down the external jugular and into the superior vena
cava. The catheter was secured in place and irrigated with
heparinized saline. The suprascapular area was recleansed and
a 2 cm incision was made. A 13-gauge needle was tunneled
subcutaneously from a dorsal incision through to the ventral
neck incision. The catheter was then threaded through the
needle and out the dorsal incision, and the needle was
removed. The catheter was then passed through a stainless
steel spring cable, secured with sutures and autoclips, and
the cable with the catheter was passed through a ventilation
hole of a metabolic cage top, and connected to a swivel on the
cage top. The rats were weighed with the cage top and then
placed in the metabolic cage.
Catheter patency was maintained with daily flushes of 0.5
mL heparinized saline (10 U/mL). At the end of surgery, 0.1
mL of the antibiotic cefazolin sodium USP 500 mg (Marsam
Pharm., Inc., Cherry Hill, NJ) was administered to four of the
rats in the IV group.
Diet and TPN Solution Preparation
The AAD, which was consumed orally, and the TPN solution
were formulated based on the nutritional needs for the growth
and development of a normal rat (Appendix B: Tables B1-B4)
(40,41). Both diets contained a mixture of all the amino
acids, carbohydrates (Appendix B: Table B1,B2), vitamins, and
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minerals required for rats (Appendix B: Tables B3-1, B3-2, and
B4). Fluoride was not added to the diets since no growth or
other benefit has previously been found from addition of
fluoride to rat diets (13,42).
Fat requirements for the rats also were provided
(Appendix C: C1, C2). In the AAD, the soybean oil and glycerin
were added in similar caloric ratios as provided in the
commercially-available, intravenous fat emulsion used in the
TPN solution. The small amount of egg yolk phospholipids
found in the intravenous fat emulsion was not present in the
AAD, however, it has previously been suggested that this
component contains no essential nutrients and can be
considered unnecessary in the oral diet (41).
Zinc was added as zinc sulfate (52.87 mg) to provide
respectively a final concentration of 12 mg Zn/Kg diet and
4.16 mg Zn/Kg TPN solution (12 mg Zn/2.886 Kg TPN solution).
Both the AAD and the TPN solution had similar kilocaloric
distribution. The AAD contained 3.84 kcal/g with 22.2% from
the amino acids, 68.6% from dextrose, and 9.2% from fat.
Nitrogen content of the AAD was 33.5 mg/g, or approximately
8.72 mg of N/kcal.
The TPN solution formulation is that described by Miyata
et al. (Appendix B) (42). The solution was infused at 1.7
mL/hour/day, and supplied 1.18 kcal/g or 1.32 kcal/mL
(specific gravity was 1.115 g/mL) . Approximately 21.7% of the
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kilocalories were from the amino acids, 67% from dextrose, and
11.3% from fat. Nitrogen content of the TPN solution was
10.08 mg/g, or approximately 8.54 mg of N/kcal.
Daily Zn intake was calculated by multiplying the Zn
concentration of the diet or TPN solution by the respective Zn
intake or infusion and dividing by three, during each three-
day collection period.
Preparation ofteaioAcid Diet (AAD)
The amino acid mixture was combined with the vitamins,
choline-chloride, and minerals and this was mixed with the
dextrose (Appendix C: Cl). The soybean oil and glycerin were
added to the other ingredients, and the completed mixture was
stored at 4*C.
Preparation of the TPN Solution
The amino acid mixture was combined with the dextrose,
slowly heated, and then cooled (Appendix C: C2). The minerals
and vitamins were mixed with the other ingredients, the
solution was filtered through a 0.22 micron filter (MSI,
Westborough, MA) , and was stored at 40C. One day prior to
infusion, the solution was passed again through a 0.22 micron
filter, then stored at 4C. Immediately prior to infusion,
the lipids and fat-soluble vitamins were added (Appendix C:
C2).
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Collection of Bamples
BSGroup:
On day 13 of the experiment, the BS rats were killed.
After exsanguination, the blood was placed in labeled
polystyrene tubes, coagulated and centrifuged. The separated
serum was pipetted into polystyrene tubes and frozen at -200C.
The liver, kidney, lung, heart, gastrocnemius muscle (left
leg), testicle, and femur bone (left leg) were dissected free,
rinsed with DDI water, blotted dry and weighed. After
dissection of the small intestine, residuals in the lumen were
removed, the tissue was rinsed with DDI water and blotted dry.
All tissues were placed in polystyrene freezer bags and frozen
at -200C. All feces and urine were frozen at -200 C.
Zn balance was determined by the following formula: Zn
balance = Zn intake - (fecal Zn + urine Zn).
CON, IV, and OF Grou s:
On day 28 of the experiment, rats in the CON, IV, and OF
groups were killed as previously described and femurs,
gastrocnemius muscles, viscera, and sera were collected by the
same method described for the BS group and frozen at -20C.
The consumption of AAD, infusion of TPN, and collections
of feces and urine were recorded every third day.
Preparation of Glassware for Bample Digestion
Prior to use, all glassware was soaked in a detergent
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solution, and rinsed with deionized water. The glassware was
then resoaked in a 20% nitric acid solution prepared with DDI
water, rinsed again with DDI water, and then rinsed with a
0.001 1 EDTA solution. A final rinsing with DDI water
completed the preparation of the glassware for sample
digestion (Appendix D).
Digestion of Samoles
In preparation for digestion, wet tissue samples, and
feces for each rat were weighed and placed in Erlenmeyer
flasks. Two-mL urine samples also were collected. National
Institute of Standards and Technology bovine liver (Standard
Reference Material {SRM} 1577b, NIST, Gaithersburg, MD) served
as quality control samples for tissues and feces (except bone
and sera). Two samples of non-fat milk powder (SRM 1549,
NIST, Gaithersburg, MD) were the designated quality controls
for the femur bone, and bovine serum (SRM 1598, NIST,
Gaithersburg, MD) was the quality control for the serum
samples. Two blanks, containing only digestion reagents, were
also prepared for each sample set.
A protocol by Hill et al. (43) was applied for the dry
ashing (43000) and wet digestion of all tissues (except sera) ,
urine and feces (Appendix D). An entire set of Erlenmeyer
flasks containing tissue or feces was placed into muffle
furnaces for dry ashing, prior to continuing with the wet
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digestion protocol using nitric acid and hydrogen peroxide
(Appendix D) (43). Samples were then transferred
quantitatively and brought to a final volume of 5 mL, poured
into polystyrene storage-tubes (washed with EDTA), and
refrigerated at 40C.
The urine was prepared for digestion by addition of
hydrogen chloride (HC1) and then digested according to the
protocol by Hill et al. (Appendix D) (43). Samples were
transferred quantitatively and brought to a final volume of
2.5 to 5 mL.
Sera were prepared for direct assay by AAS, and stored in
polystyrene tubes at -20C. There was no serum sample for one
rat in the CON, BS, and IV groups.
Analysis _of._Sample ls
Samples were prepared for AAS aspiration by appropriate
dilution with 0.1 1 HCl (or diluted with DDI water for serum) ,
to bring the Zn concentration of the samples within the range
of the standard. A flame atomic absorption spectrophotometer
(Perkin Elmer Model 5000, Perkin Elmer, Norwalk, CT) was used
to analyze the Zn concentration in the samples (Appendix D).
The spectrophotometer was stabilized after positioning of the
Zn lamp, setting the resonant wavelength, and igniting the
flame. The instrument was brought to equilibrium with a 0.1
14 HCl solution and calibrated using the appropriate Zn
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standards that were prepared to cover the linear absorbance
range (0.25 ppm to 2.00 ppm) of the trace element. Zn
standards were aspirated at the beginning of the sample
aspirations, and then every 5-10 samples to ensure appropriate
calibration.
Standard reference materials and blanks were aspirated
with their corresponding sample set. Triplicate sample
aspirations completed the sample analysis for Zn concentration
by AAS (Appendix D). The blanks analyzed with the sample sets
were negligible in their Zn concentrations, but were still
subtracted from the sample Zn concentration readings for
accuracy of total Zn content. Weights or volumes and
dilutions of the tissues, feces, urine, and sera were used
with their respective AAS readings to attain final Zn
concentration of the respective sample.
StatisticalAnalysis
Statistical analyses were completed to determine
significant differences among dietary groups for each dietary
treatment. Means for whole body weight, energy intake, total
Zn intake, total Zn output, Zn balance, and tissue Zn
concentrations were analyzed by a one-way analysis of variance
(ANOVA) (p<0.05). All values are expressed as means
standard deviation (SD).
23
Results
DigcestionStnad
Standards for bovine liver, serum, and nonfat milk powder
were analyzed by the AAS. Certified values were 127 16 pg
Zn/g in bovine liver, 0.89 0.06 pg Zn/g in bovine serum,
46.1 2.2 pg Zn/g in nonfat milk powder, and analyzed values
were 119.6 5.1 jg Zn/g, 0.89 0.0 jg Zn/g, and 44.25 0.05
pg Zn/g respectively. Only one (of two) bovine liver
standards, analyzed with a feces set, was lower than the
certified range at 27.2 pg Zn/g.
Bod Weights
Rats gained an average of three g per day (Table 1) in
the first nine days. There was no significant difference in
the pre-surgical body weights (day 9) of the rats in the four
groups (Table 1). Body weights of the CON group from the pre-
surgical weight period to the feeding weight period (day 13)
was significantly higher (p<0.01) than the BS, IV, and OF
groups. The CON, IV and OF groups continued the respective
diet treatments (days 14-28), and the body weights did not
differ from the feeding weight to final weight (day 28).
Energy Intake
Energy intake during the acclimation period (days 1-9)
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did not differ significantly among the CON, BS, IV and OF
groups (Table 2). In the postoperative recovery period (days
10-13), the rats in the CON group consumed significantly more
food (p<0.o1) than the rats in the BS, IV and OF groups. The
rats in the CON, IV, and OF groups continued the respective
treatments (days 14-28), and no significant difference in
energy intake among the groups occurred.
DailY ZnIntake
Daily Zn intake during the acclimation period (days 1-9)
was not significantly different among the groups (Table 3).
While recovering from surgery (days 10-13), the CON rats had
a higher (p<0.01) Zn intake than did the BS, IV, and OF rats.
During the treatment period (days 14-28), the daily Zn intake
by the IV rats was significantly higher (p<0.01) than that of
the CON and OF rats. The IV rats received approximately 1000
pg Zn/kg/day, whereas the CON and the OF rats consumed
approximately 800 Jg Zn/kg/day.
Although feces and urine were collected every three days
from the recovery period (day 10), only two sets were analyzed
by AAS. The total Zn intake for Collection #3 (days 17-19) of
the experiment showed there was an approximately 20% higher
(p<0.O1) intake of Zn by the IV group compared to the CON and
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OF groups (Table 4). However, the total Zn intake for
Collection #6 (days 26-28) did not differ significantly among
the groups.
Total Zn output via urine and feces for Collection #3 and
Collection #6 showed no significant difference among the CON,
OF and IV groups, and Zn balance for Collection #3 and
Collection #6 did not differ among the groups.
Tissues
Zinc concentration in the liver (Figure 2), kidney
(Figure 3) and lung (Figure 4) was significantly higher
(p<0.01, p<O.O1, and p<0.01 respectively) in rats of the IV
group compared to those in the CON, BS, and OF groups. Small
intestine Zn concentration in the rats of the IV group was
significantly higher (p<0.03) than that of the CON and BS
groups, but did not differ from that of the OF rats (Figure
5). Zinc concentration in the small intestine of the OF rats
also was not significantly different when compared to that of
the CON and BS rats (Figure 5).
Zinc concentrations in serum (Figure 6), heart (Figure
7), muscle (Figure 8), testicle (Figure 9), and bone (Figure
10) were not significantly different among the four groups.
29
co (n r-
r-i
04
+1 +1 +1
cy ch
(N %10 (n
z co 1 r%
N 04 tP +1 $1 1
P
1% u co NP LO
M s i r d
>4 044
N t"
+1 +1 +1
z ON
M Cj co (Y)
14
co 0) C^
N CN LO
-1-1 +1 +1
co CD
1 Ln
04 F-1 rd c 1
+1 +1 +1
>4 co c "f
04 0
cl
+1 +1 +1
E-+
r-1
1-9 s-1
U) Itr
tt! +1
t4 04 (15 Y
3
t} :r 0, 0 S9 9
40
x
s
w
2 7' 10
sxa< y
26
CON
I All
Figure 2. Zinc liver Fiscber-344 s
fed either orally (CON, BS, OF) or
i
Means (n=6) SD
31
gncr
r It
28144
2437 32 3 9
I,
R AT '. 1. 1-
Figure . concentration Zinc kidney Fischer-344 rats
fed either orally (CON, BS, OF) or
intravenously 
Means
3
s40,
g 1yF
:23.46
tea, 19.45 19 , 2 2,18 0 
ahy 6 i 
20- 59,
4 00
n 07 7 41
n f
.,,.., .,u,,.,. , aza. d.a ,.3 .a4 u.<a. .. ,xMa - ... a , M., 3 ri F..,.,,,e, 
.,., a a,,. .. - ,.. ., ea ,,.a. " .w. re m 
a., .,.o- .x, _..., ,. . .atsmam..,+.t ,. .v e ,U.,,. " 
'
RAT GROUP
Figure 4. Zinc concentration in lung of Fischer-344 rats
hed either orally (CON, BS, OF) or0intravenousls=
33
u v 
3 8 3" 61
4ti
5
40 FaD!
q 
S
066
"27 .4 55 66 4 b,
'oq
'91 1,86
yy 
s
*^t 4
r, 5
Figure 5. Zinc concentration in small intestine of Fischer-344 rats
fed either orally (CON, BS, OF). or
intravenously a Means =)
Means vi different suprascripts , r significantly different
34
A
3
i ? a 3 .... , 6 i r
a 1,79 0-36 "a' WN e ,
am 
..
4 
S
1 59 0,36
{ 
~ 
, S 
kg3 1
K K Y 'i
a a
3 ti j
ti
1 ,, 8 tit T] S 
_ 
4
Figure i concentration in serum of Flischer-344 rats
fed either orally (CON, BS, OF) or
intravenously (IV).
Means =)
35
ryt t
S
fij h
r 
1
F
-' 
i
f 
a
t
;mil kg
J
20,36 7-180,
Y4 >. Si a 29, 3305 9 2 4a. i y
4
+ S. bit q q "i { T
t a \
a g
R % h' (
Fischer-344 ratsconcentration 
inc Figure 7. Z'
intravenously fed elither orally 
(CON, BS, OF) or
.
s_)
3b
4T &; R a
t
wt! 4
has
f
4 t'61' 3 -3
0, 4,Ei
41
.1......,
g I eye ~ 
t it ,,
A 'ntt 1, -'
Figure . Zinc concentration i muscle Fischer-344 rats
fed elither orally (CON, BS, OF) or
intravenously ).
Means )-
7
t40
_,
29
30,70 1,88 5 2,09
iva. 3
f l7
a t g
2
A y
\
A 4
R'A T R
Figure 9. 1 concentration iin testicle of Fischer-344 rats
fed either orally (CON, BS, OF) or
1
Means
3
1501 Al
R
S
\ 1
y 
v
120 1041,69 M27104,03 9,80
996,27 10,,20 * w a
w
90
. .. 
j e
3 a i t
z DR
71
RAT GROUP
Figure o concentration Ziinc Iin bone of Fischer-344 rats
intravenously fed either orally (CON, BS, OF) 
or
# Means (n=6) SD
3
Discussion
All the rats in this study consumed adequate food during
the acclimation period (days 1-9) to achieve normal weight
gain (an average gain of three g per day). Nutritional
adequacy was achieved by the AAD because it provided normal
growth and development of the rats; they consumed
approximately 12 g/day of the AAD. Normal weight gain
confirmed the acclimation of the rats to the laboratory during
those nine days.
The mean body weights for the groups were similar at the
time of surgery. After the catheter placement, the BS, OF and
IV rats had decreased food intake (approximately four g
AAD/day) that preceded the weight loss, reflecting a normal
response to the stress of surgery (42). This response
appeared uniform during the recovery period, as reflected in
the similar weight loss among the three groups. The final
body weight and consistent energy intake of the CON, OF and IV
rats throughout the treatment period (days 14-28), supported
the isocaloric and isonitrogenous properties of the AAD and
the TPN solution and the ability of the diet regimens to
support growth, development and anabolism in the rats.
However, during the treatment period, the OF group showed the
greatest food efficiency with an approximately 40 g weight
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increase in 15 days, compared to an approximately 30 g weight
gain for the CON and IV groups. Though the OF and IV groups
recovered from the surgery, the rats in the IV group never
developed beyond the pre-surgical state as evidenced by final
body weight. Thus the IV rats were exposed to an increased
level of stress compared with the OF rats, after surgery.
Daily Zn Intake
During the acclimation period the daily Zn intake was
constant in all the rats. Due to the decrease in food
consumption during the post-surgery recovery period, Zn intake
decreased in the BS, OF, and IV groups.
At the initiation of the diet-treatment protocol for the
OF and IV groups, the main focus was administering a TPN
solution that had isocaloric and isonitrogenous properties,
similar to an oral diet (41,42). In order to achieve
isocaloric and isonitrogenous properties, the TPN solution was
adjusted to attain the kilocalories and nitrogen that a rat
would receive orally each day, while also considering
appropriate daily intravenous infusion of fluids for a rat.
It was assumed that trace element concentration would have
adjusted accordingly, however this was not the case.
Calculations estimate approximately 20% more Zn was received
by the IV group (approximately 1000 pg Zn/kg body weight/day
for the IV group, versus 800 pg Zn/kg body weight/day for the
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OF group).
The greater Zn intake by the IV group may not have been
the dominant factor in causing the increased Zn concentration
seen in some of the tissues, although it may have played a
role. Zinc availability, in combination with the sequestering
of Zn in certain tissues as a response to continuous stress
(44,45,46,47,48), may have been the dominant factors
contributing to increased Zn concentrations in some tissues of
the IV rats. The CON rats did not undergo surgery or stress.
The OF rats were exposed to the stress of surgery but were not
exposed to continuous stress (e.g. continuous IV fluids,
flushing of lines, antibiotics, etc.) as were the IV rats.
Zn Balance
Only two of the six three-day collection periods were
analyzed and therefore reflect limited information on the Zn
balance of the rats. The similar total Zn output among the
groups indicated that the IV rats did not necessarily excrete
more Zn than the OF rats even though they received more Zn.
Stress factors, retention and/or intravenous availability of
the 20% additional Zn received by the IV rats could have
resulted in the increased tissue deposition documented.
Positive Zn balance in the CON, OF and IV groups confirmed the
Zn adequacy of the TPN solution and the oral diet.
The OF and IV groups appeared more efficient in positive
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Zn balance than the CON group as evidenced by higher Zn
balance values. In the IV group this can be explained by the
greater intake and availability of Zn. In both the OF and IV
groups, there appeared to be greater efficiency of Zn
retention as evidenced by the lower output values. It is
possible that after the post-surgery recovery period where the
OF and IV rats were exposed to stress and weight loss due to
decreased energy and Zn intake, these rats transitioned into
an anabolic phase (the OF rats more efficiently), resulting in
greater retention of Zn compared to the non-stressed CON rats.
Tissues
Liver and Serum:
The liver is a known site for activity of newly absorbed
Zn (45,49,50,51,52). Higher Zn concentration in the liver of
the IV rats may be reflective of metallothionien metabolism.
Once Zn is circulating in plasma, bound to albumin, it can
enter a liver cell as 1) free Zn in a labile pool, or 2)
become part of a metalloprotein Zn pool (45). Zinc in the
liver cell is generally distributed among metalloproteins
(which assist in Zn exchange) , organelles, and cell membranes,
among other cellular components (44,45). One of the most
widely studied metalloproteins is metallothionein (WET),
especially its activity in the liver, kidney, and intestine.
Metallothionein, a predominantly Zn-containing protein, seems
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to play a significant role in Zn homeostasis
(45,46,49,50,53,54). Even in the early years of Zn research,
it was noted that rats fed a high Zn diet (1000 mg/kg) for 10
days had a significant increase in the Zn concentration of
their liver, intestine, and kidney, the Zn likely bound to MT
(55). Similar results were found in the tissues of the IV
rats which received approximately 1000 pg Zn/kg/day
intravenously. In later years, Blalock et al. found that rats
fed increasing amounts of Zn in their diets had associated
increases in total MT in the kidney, but not in liver (56).
Other researchers have found increased liver Zn content with
increasing dietary Zn supplementation (52,55,57).
In the liver, certain physiological factors, including
trauma, stress, and inflammation, as well as the
administration of Zn can induce MT
(44,45, 46,47, 48, 53, 54, 58, 59). These inducers can promote
increased transcription of the MT gene, involving increased
synthesis of MT mRNA (44, 60) . This cycle then boosts Zn
accumulation in liver by increasing MT protein which binds Zn,
often decreasing serum Zn (44,45,46,48,49,60,61,62,63,64,65).
This redistribution of Zn may be a regulating and protective
mechanism of the body to assist the liver in having Zn
available for increased protein synthesis in response to
stress (i.e. to supply Zn for the enzymes required for DNA
synthesis) (44,45,47). The BS rats did not show this response
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four days after surgery, however, they received no substantial
nutrition during that time period. DiSilvestro and Cousins
have documented and postulated that serum Zn and hepatic MT Zn
may not always present an inverse fluctuation, in response to
stress events, and also that examining serum at only one
period in the experiment may result in failure to observe a
transient decline in serum Zn (48).
The present study documented a significant deposition of
Zn in the liver of the IV rats, however, no significant
difference in serum Zn concentration was seen among the
groups. It is possible that the greater Zn availability and
the approximately 20% higher Zn intake by the IV rats may have
prevented a drop in serum Zn that could have occurred in
response to the stress, inflammation, and/or intravenous Zn
infusion.
When in anabolism, after recovering from a catabolic
phase, other tissues have been documented to contribute to
maintaining serum Zn levels within normal limits, without
necessarily affecting the tissue Zn concentrations (29,31).
This contributory pool is believed to be located mostly in
bone, liver and plasma (29,31). It is also not known to what
extent some level of blood sample hemolysis (which can
increase serum Zn values) may have affected serum Zn
concentrations (14). It is evident that serum Zn is not
always reflective of body tissue Zn status (14,29,30,31).
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However, one of the goals of this study was to contribute
additional information on Zn metabolism to help shed light on
better ways to assess Zn status in humans. Some have
suggested examination of Zn concentration in the bile (35).
Others have suggested measurements of plasma MT concentrations
(29) and pancreatic y-glutamyl hydrolase enzyme activity (66) .
Nevertheless, it appears that until an accurate, standardized
Zn-analysis method is developed, it is imperative to consider
the developmental stage of the individual and to measure Zn
losses in stool, urine, and fistulas (if applicable) to
precisely determine Zn requirements during TPN.
Parenteral Zn has been shown to increase liver MT
expression (45,53,60). Richards and Cousins found that after
24 hours of intraperitoneally administered Zn sulfate, Zn-
binding-protein-Zn (MT-Zn) increased in the liver and the
small intestine, while serum Zn concentration decreased
significantly (where as at 8 hours serum Zn had been
substantially higher than controls) (50). However, in that
study, the authors found that 48 hours after the Zn injection,
MT-Zn had decreased in the liver (although not in the small
intestine) and the serum Zn was within normal limits (50).
Apparently, a single injection of Zn can vary the liver and
serum response in rats at different examination times. The IV
rats received continuous intravenous infusions of Zn sulfate,
which may have promoted an increase in liver Zn concentration.
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Huber and Cousins found that liver MT synthesis increased
after injection of Zn chloride in rats (67). Simple saline
injections have been documented to increase liver MT mRNA
(56), which can promote Zn retention. Therefore, a combination
of parenteral administration of Zn, possible inflammation, and
the general stress of the IV rats receiving continuous TPN as
a sole source of nutrition may have promoted increased liver
Zn concentration.
Zinc and its role in wound-healing in normal rats was
studied by Elias and Chvapil (68). The authors found that
after a skin incision wound, and subsequent Zn treatment, Zn
concentration increased in the skin wound area and in the
liver, but not in the serum. Further investigations indicate
(44,45,47,60), that stress inflicted by surgery may have been
an additional influence that caused the influx of Zn, into the
liver, in the IV rats when compared to controls. The greater
Zn availability and possibly the higher Zn intake in the IV
rats may have been additional factors causing a significantly
higher liver Zn concentration compared to the OF rats, who
also underwent surgery.
Small Intestine:
Sites of absorption and excretion, such as the small
intestine and the kidney, as well as the liver, seem to be the
sites of most activity for newly absorbed enteral and
parenteral Zn (31, 45, 50 , 51, 52, 53, 56, 69). Small intestine Zn
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concentration was increased in rats by feeding a high-Zn diet
(31). Parenteral administration of highly available Zn would
be expected to increase Zn concentration in the small
intestine of the IV rats, compared to controls. The
approximately 20% higher zinc intake by the IV rats may also
have played a role.
The reason why the small intestine Zn concentration of
the OF rats was not different from the CON and IV rats is
unclear. However, during the treatment period, the OF rats
apparently must have shared some similar characteristic(s)
with both the CON and the IV rats. Studies of rats during Zn
depletion-repletion diet regimens have documented increased Zn
concentration in the small intestine after rats were repleted
with Zn (31,50). During the recovery period, the OF and IV
rats entered a catabolic phase with documented weight loss and
negligible energy and Zn intake. They were then repleted
nutritionally for two weeks, prior to being killed.
Therefore, if the OF and IV rats had an increase in MT-Zn in
the small intestine due to Zn repletion, it was likely
tempered for the OF group (consuming an oral diet similar to
the CON group), after entering anabolism, yet this increase
may have supported their similarity in small intestine Zn
concentration to the IV rats. The IV rats continued to be
exposed to stress during the treatment period (e.g. continuous
intravenous infusion, flushing of lines, antibiotics, etc.),
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where the OF rats did not.
Hempe et al. recently studied male CD-strain/Sprague
Dawley rats and found that administration of intraperitoneal
Zn sulfate increased MT gene expression in both intestine and
liver, and this may serve to regulate protective metabolic
changes occurring from high exogenous Zn intake (60). For
example, increased MT synthesis in the intestine may decrease
Zn absorption (60). Intraperitoneal administration of Zn
sulfate and Zn chloride also have increased the synthesis of
MT-Zn in the small intestine (50,53). If the IV rats received
a substantial amount of available, intravenous Zn, MT gene
expression may have promoted higher Zn concentration in their
small intestine compared to the CON rats. The BS group did
not receive parenteral nutrition and therefore would not be
expected to show this response.
Schneeman et al. have observed that bile, pancreatic
juice, and intestinal mucosa seem to be sources of endogenous
Zn (69). If the IV rats were not secreting as much bile and
pancreatic juice as the OF rats who were eating, liver Zn may
have been maintained better in the IV rats (especially since
liver bile outflow to the intestine is 1.5-2 times greater
than pancreatic juice (69)). Alternatively, the OF rats had
more opportunity to activate the bile system with enteral
feedings, and bile secretions into the intestine may have
caused the lack of significant difference in small intestine
49
Zn concentration between the OF rats and the IV rats. Also,
the OF rats probably had a chance to reabsorb intestinal
secretions of bile Zn, adding to their overall Zn
concentration in the small intestine.
Neither inflammation nor infection were evaluated in the
rats of the present study. However, the rats response to
general stress and stress mediators, if present, may have
influenced intestinal Zn accumulation of the OF and IV rats
(70). The BS rats went through surgery but were killed prior
to initiation of feeding and probably did not have a chance to
experience further possible stresses.
Kidney:
The kidney has been mentioned as an active site for newly
absorbed Zn (31,45,51,52,56,71,72). This alone may be one
reason for significant increased kidney deposition of
intravenously administered and available Zn in the IV rats,
and in larger quantity than that received by the OF rats. As
in the small intestine, studies of rats during Zn depletion-
repletion oral regimens have documented that Zn concentration
increased in the kidney after Zn repletion (31) and that
kidney Zn concentration increased in rats by feeding a high-Zn
diet (51,52,55,57,71,72).
Blalock et al. have postulated that the kidney acts as a
Zn regulator which can control urinary output of Zn and/or
have a role in detoxification, as they observed when increased
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Zn-containing MT synthesis occurred in the kidneys of rats
consuming adequate or supplemented Zn diets (56) . Considering
the same can occur, especially in rats fed intravenous Zn,
this may explain the higher Zn concentration in the kidneys of
the IV group which received approximately 1000 pg Zn/kg/day
compared to the CON and OF rats who consumed approximately 800
Mg Zn/kg/day.
Increased urinary Zn output was not noticed in the
balance study during the two treatment period collections
analyzed. As in the study by Blalock et al., enhanced MT
production may have occurred in the kidneys of the IV rats
which may have been important in the processing of Zn to
prevent urinary loss of the trace element and to prevent
kidney and urinary tract damage (56).
It has been documented that, unlike the liver, most
physiological stress and its mediators do not appear to
promote substantial MT induction in the kidney (47).
Lung:
In the study by Chvapil et al., the lung was unable to
increase Zn content with increasing dietary Zn supplementation
(55). Kang et al. also reported that Zn concentrations of
lung tissue did not change following diets containing 1.3
gg/g, ss Mg/g, or 550 pg/g of Zn (57). Also Cousins and Lee-
Ambrose found that lung MT mRNA levels did not change
significantly by increasing dietary Zn intake (52).
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It has been shown previously that a substantially high
concentration of Zn (30 pg/g wet weight) in an organ was
necessary for production of Zn-thionein (53,54). Of the four
rat tissues demonstrating significantly elevated Zn
concentration, this finding was reflective, for the most part,
in the liver and kidney of the IV rats, and the small
intestine of the IV and OF rats. The Zn concentration in the
lung of the IV rats was well below 30 pg/g wet weight (23.46
pg/g 1.84), and yet the IV rats showed an appreciably higher
lung Zn content. However, it appears that in this population,
administration of a substantial amount of intravenously
available Zn increased lung Zn concentration significantly in
the IV rats.
Heart. Muscle, Testes. Bone:
The Zn concentration in heart, muscle, testes, and bone
of the rats was not affected by: 1) the stress of surgery, 2)
a higher Zn intake by the IV rats, and 3) two different routes
of nutritional administration. Similar studies have supported
these findings. In a study by Chvapil et al., the heart,
muscle, testes, and bone Zn concentration did not
substantially increase with increasing dietary Zn
supplementation (55). When Zn concentration of water ranged
from 2.5 to 40 pg/mL, no changes in the Zn content of heart,
leg muscle, testes, and liver were documented (72).
Sherman et al. suggest that in the rat heart, Zn is
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mainly present as metalloproteins and metalloenzymes involved
With metabolic function and structural responsibilities (32).
Larsen and Sandstrom have also documented consistent heart Zn
concentration with increasing dietary Zn intake (51).
The Zn concentration in muscle appears to be maintained
very consistently (31,51), especially in rats fed Zn-adequate
diets (73). Giugliano and Millward documented no differences
in rat gastrocnemius muscle Zn concentration after the rats
received adequate (55 mg Zn/kg) or severely deficient (0.4 mg
Zn/kg) Zn diets fed in Zn-depletion or Zn depletion-repletion
diet regimens (31).
Although a study of rats during Zn depletion-repletion
diet experiments documented increased Zn concentration in the
testes after Zn repletion and that testes Zn concentration
increased in rats (as compared to baseline rats) by feeding a
high-Zn diet (31), Canton and Cremin studied the effects of Zn
depletion and repletion on rat tissue and found Zn
concentration maintained in the testes (66). Recently, MT has
been located in rat testes and other parts of the male
reproductive organs, and Nishimura et al. stated that this
"further supports the notion that MT may be physiologically
associated with Zn storage and transport... " in the testes
(74).
In rats, it appears that Zn continues to deposit in bone
when fed both Zn-adequate and high Zn diets (51,73). In a
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recent study, Zhou et al. have produced data suggesting there
are two Zn pools in the bone skeleton: 1) a quick turn-over
pool (10-20 % of total Zn) from which Zn is easily removed
when needed to meet soft tissue needs, and 2) a slow turn-over
pool from which Zn cannot be used without bone loss and a
decrease in growth (73). Giugliano and Millward have data
suggesting that Zn is conserved in body tissues during
catabolism or is redistributed from bone and released into
plasma where it is quickly taken up by other priority tissues,
such as muscle, to allow growth (31). This supports
consistency in muscle Zn concentration. This may also support
why the BS rats never showed any significant difference in
tissue Zn concentration compared to the CON rats, even though
they were killed immediately after undergoing a catabolic
post-surgical recovery period.
Zhou et al. found that with borderline Zn restriction,
rats release and use Zn from the bone's quick turn-over pool
to maintain Zn homeostasis, and that not until four weeks of
Zn restriction is a substantial decrease in rat growth seen
(73). Zhou et al. also agreed with King who postulated that
changes are not seen in plasma Zn concentrations until body Zn
homeostasis cannot be maintained by slowing of growth or
reduced Zn excretion (29,73). Since the CON, IV, and OF rats
were maintained in positive Zn balance, no need to mobilize
bone Zn stores probably arose (except for a possible
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utilization of the Zn rapid turn-over pool during the 4-day
recovery period for the BS, IV, and OF rats, where there was
a trend toward lower bone Zn concentration in the BS rats),
hence supporting the consistent bone Zn concentration in all
the groups.
Zinc Toxicity
The question of Zn toxicity arises when addressing higher
amounts of parenteral Zn compared to enteral Zn. The Zn
intake of the rats in either the OF or IV groups did not come
near the level of Zn intakes reported in the literature to
have adverse effects on rats. Nevertheless, the importance of
avoiding excess intake of Zn enterally is evident (57,75).
Even more important would be the concern of avoiding excess
intakes of Zn parenterally when no intestinal absorptive
factors are present.
Kang et al. divided rats into three groups and gave them
ad 1ibitum access to a commercially prepared Zn-deficient diet
containing 1.3 Ag Zn/g diet (57). Group A received just this
diet, Group B received the same diet supplemented with Zn
carbonate (55 pg Zn/g diet), and Group C received the same
diet supplemented with high amounts of Zn (550 Mg Zn/g diet)
(57) . Kang et al. found that the rats in groups B and C had
similar weight gain and food efficiency ratios (gram of body
weight gain per gram of food consumed), and proposed that a
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550 yg Zn/g oral diet was not toxic for the rats (57).
However, they found that the liver and kidney Zn
concentrations increased with higher dietary Zn intake, but
the iron concentrations of those tissues decreased with
increasing dietary Zn (57). Yamaguchi et al. have found oral
administration of 1000, 10,000 or 100,000 pg Zn/kg/day to
weanling rats for 30 days may (especially at the higher doses)
inhibit rat bone growth and calcification, and significantly
decrease femur bone weight and calcium content (75).
A TPN solution inadvertently providing 23 mg Zn/L daily
(instead of 2.3 mg Zn/L), in addition to approximately 3.1 mg
Zn/L of mean level Zn contaminant for a total of 25 to 26 mg
Zn/L daily, resulted in hyperamylasemia in 6 of 7 human
patients (76). None of the patients showed clinical signs of
pancreatitis (76).
A death occurred from an inadvertent infusion of 1.7 g of
Zn (7.4 g of Zn sulfate) over a 60 hour period in a women with
Crohn's Disease, receiving TPN (77). Symptoms prior to demise
included hypotension, pulmonary edema, diarrhea, vomiting,
jaundice, oliguria, cardiac arrhythmias, hyperamylasemia
without evidence of acute pancreatitis, acute anemia and
thrombocytopenia (77).
Tisue etetio ofZn ithTPNAdministration
The Russian study by Poriadkov et al. showed results
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consistent with this study, where liver Zn concentration
increased after receiving complete intravenous nutrition (34).
In the study by Yokoi et al., the daily Zn
supplementation in their TPN was similar (approximately 1312
hg Zn/kg body weight/day) to the present study's
(approximately 1000 pg Zn/kg body weight/day), and their Zn-
deficient diet contained similar Zn concentration (14.2 mg
Zn/kg diet) compared to the present study's diet containing
the requirement of Zn for rats (12 mg Zn/kg diet) (15). Their
results are similar to the present study's in the increase Zn
content seen in the liver with the TPN group compared to the
diet group, and the consistency of Zn content seen in the
heart, testis, muscle, and bone. It is possible that the
slightly higher infusion of Zn in their TPN group may have
been a factor in the higher plasma Zn concentration
documented.
The study by Matsuda et al. is dissimilar to the present
study since Zn concentration in the control oral diet was
almost three times more than in the Zn-requirement-containing
diet in the present study (16). Their Group B received only
trace amounts of Zn in the TPN, Group C received only 10 % of
the Zn the IV group received in the present study, and Group
D received only 31 % of the Zn the IV group received in the
present study. Yet muscle and testes showed constant Zn
concentration which affirms the Zn concentration stability in
57
these tissues also seen in the present study. Since the bone
is a large mass of tissue, any variation in the bone Zn pool
found in the Matsuda et al, study was seen only when Zn intake
was substantially low in the TPN, Therefore, in the present
study, changes in the bone Zn pool would probably have been
likely only with substantially excessive Zn intake.
It is possible the lower Zn infusion in the TPN solution
by Matsuda et al. caused no significant change in their rat's
liver Zn concentration, but that the higher Zn infusion in the
IV rats of the present study did cause a change. Matsuda et
al. found varied kidney Zn concentration, depending on the Zn
infusion, and this helps support the higher kidney Zn
concentration in the IV group of the present study, which
received 20% higher Zn intake. The infusion of only 30 % of
the Zn the IV rats received in the present study, caused no
significant difference in Zn heart concentration between
Groups D and A in the Matsuda et al. study. The heart Zn
concentration in the present study also showed stability with
adequate to higher Zn intake.
In Yamato's study, a high Zn infusion with TPN showed
deposition of Zn in key tissues which reflects similar
findings in the present study (35). Although in Yamato's
study, Group D received 4.5 to 6 times the daily Zn of the
present study, Zn did deposit significantly in the liver,
small intestine, and kidney compared to controls. Zinc
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infusion was so high however, that serum, muscle and bone Zn
pools apparently also showed higher Zn concentration compared
to controls. still, unlike the present study, lung Zn
concentration did not differ compared to controls.
In another investigation, Matsuda et al. intravenously
injected four groups of rats for seven days with a trace
element preparation containing Zn (36). The second group of
rats received intravenous injections of Zn (784 psg Zn/kg body
weight/day) similar to the daily Zn infused in the TPN of the
IV rats in the present study (1000 jg Zn/kg body weight/day).
However, Matsuda et al. found that this dose of intravenously
administered Zn, for the most part, did not affect tissue Zn
concentration (except in plasma), as did the higher Zn doses
(36). However, rats in the present study were fed or infused
Zn-containing diets and TPN for twice as long as ones in the
study by Matsuda et al., and also received the trace element
in a form containing other nutrients (and over 24 hours daily,
rather than a single-dose daily). This may have improved Zn
metabolism and tissue availability, possibly having a role in
causing its tissue accumulation.
Matsuda et al. also found the highest dose of intravenous
Zn (7840 pg Zn/kg body weight/day) toxic and deadly, as it
killed all the rats in that group. Those rats received almost
eight times the dose of Zn administered to the IV rats in the
present study.
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In summary, intravenous administration of Zn in TPN can
cause elevations in tissue Zn concentrations in rats. In view
of these findings, more research is recommended to determine
intravenous Zn requirements and/or possible risk of toxicity
for long-term Zn administration.
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The effect of TPN on Zn retention in tissues of Fischer-
344 rats was evaluated and compared to rats consuming a Zn-
supplemented oral diet. Findings revealed:
1. The BS, OF, and IV rats experienced a 4-day catabolic
state during the recovery period after surgical catheter
placement. The OF and IV rats then entered a recovery
period with documented weight gain. The TPN regimen was
able to maintain the IV group rat weights during the
treatment period, but with no obvious growth beyond the
pre-surgery condition.
2. The IV group received an average of 20% more Zn daily
compared to the OF and CON groups (p<0.01), during the
treatment period, because the TPN solution was adjusted
in order to achieve isocaloric and isonitrogenous
properties, similar to an oral diet, and Zn concentration
did not adjust accordingly.
3. No significant difference was seen in fecal and urinary Zn
output among the groups, although the OF and IV groups
appeared to have greater efficiency of Zn retention, as
evidenced by lower output values, compared to the CON
group.
4. Rats receiving intravenously administered Zn from a TPN
solution had significantly higher Zn concentration in
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liver, small intestine, kidney, and lung (p<0.01, p<0.03,
P<O.O1, p<0.01 respectively). High availability of the
intravenous Zn and possibly the higher Zn intake were
contributing factors since these organs are known to have
high Zn metabolism.
5. Surgical trauma and the continuous TPN protocol were the
factors most related to the observed Zn redistribution and
concentration in the liver, kidney, lung, and intestine.
Overall, trauma and continuous stress appeared to have
greater effect on animal Zn status than did the concentration
of Zn in the nutrient source (IV versus oral). Serum Zn is
not the best parameter to determine Zn status during stress.
In view of these findings, more research is recommended,
especially with more detailed, long-term balance studies, to
assist in determining Zn needs in TPN. Future studies to
determine TPN needs in rats may include a study which allows
rats to reach pre-surgery weight before initiating TPN
treatment, and a study to compare bile Zn concentration versus
serum Zn concentration as a measure of Zn status.
Measurement of the effect of various dosages of
intravenous Zn administration on the rate and level of
increased MT mRNA production in the cell, may also assist in
determining Zn needs in TPN.
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APPENDICES
Appendix A
Surgical Catheter Placement
1. All surgical instruments, catheters and swivel assemblies
were doubly wrapped in autoclave paper and steam
sterilized at 125 *C for 20 minutes on the day prior to
the surgery.
2. During surgery, all autoclaved instruments and supplies
were placed on a 46 x 66 cm disposable impermeable sterile
drape (Sterile Drape, ABCO, Milwaukee, WI) by means of
aseptic technique (41). Surgical masks and sterile gloves
were worn during surgery and when working with materials
in the sterile field.
3. The ventral neck, mid-scapular and suprascapular areas
were shaved, and the animal was weighed. The rat was
restrained in supine position on an animal surgical board
and the ventral neck was thoroughly cleansed with povidone
iodine, 10% solution (ABCO Solution, ABCO, Milwaukee, WI),
using sponges held with a hemostat.
4. A 3 cm midline incision was extended from above the
suprasternal notch, up the neck. A surgical drape was
placed over the animal with an opening above the incision,
and the skin flaps were autoclipped to the drape opening.
5. The surgical site was again cleansed thoroughly with
povidone iodine. The right external jugular was dissected
free and two, 6 inch pieces, of 4-0 silk suture were
placed underneath the vein, about 0.5 cm apart.
6. The 4-0 silk closest to the tail was clamped with a
bulldog clamp. Bleeding was prevented by tension put on
the vein from the silk closest to the head.
7. A small incision was made into the vein, between the two
sutures. The beveled end of a silicone rubber catheter
(Silastic, Dow Corning Co., Midland, MI), 0.02 inches in
internal diameter and 0.037 inches in outer diameter, was
threaded 2 cm down the external jugular, into the superior
vena cava. The catheter was tied in place with 4-0 silk
sutures.
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8. The catheter was irrigated with heparinized saline through
a 1.0 ml syringe that had been attached previously to the
catheter. Blood was also drawn from the catheter to
assure correct catheter position.
9. The drape was folded on itself and the rat was rolled on
its side. The syringe and catheter were kept in the
sterile fold of the drape.
10. The suprascapular area of the back was cleansed with
povidone iodine and a 2 cm incision was made. Another
sterile surgical drape was placed over the animal with an
opening over the incision and the skin flaps were
autoclipped to the drape.
11. A 13-gauge needle was tunneled subcutaneously from the
dorsal incision, behind the front leg, through to the
ventral neck incision.
12. A bulldog clamp was used to occlude the catheter on the
ventral side to prevent an air emboli. The catheter was
then threaded through the needle and out the dorsal
incision. The needle was removed and the bulldog clamp
was moved to the dorsal side.
13. The dorsal drape is again folded and the rat placed
supine. The catheter was threaded through a stainless
steel, flexible spring cable containing a flange.
14. The catheter was secured with a suture and the ventral
incision was closed with auto clips. The flange on the
spring cable was sutured with 3-0 silk to the dorsal
interscapular fascia. The dorsal incision was closed
around the spring cable with autoclips supplemented with
sawing a 3-0 silk suture to assure a tight closure.
16. The spring cable with the catheter was passed through a
ventilation hole on the cage top and the catheter and
cable were attached to the bottom port of a swivel and
secured to the cage top.
17. A 3-cc syringe was attached to a 10 cm silicone rubber
catheter (0.02 inches in internal diameter and 0.037
inches in outer diameter) which was attached to the top
port of the swivel and the cage top.
18. HepariniZed saline (10 u/ml) was flushed through the
catheter. The incision areas were again cleansed with
povidone iodine. The rat was weighed with the cage top
and placed in the metabolic cage.
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Appendix B
Table B1. Formulation of the Amino Acid Diet and TPN Solution
Amino Acid Diet # TPN Solution
Ingredient (g/Kg Diet) (g/2886 g Solution)
Amino Acid
Mixture * 205.00 205.00
Dextrose 677.42 677.42
Minerals ** 74.869 74.869
Vitamins *** 1.770 1.771
Soybean Oil 34.20 -----
Glycerin 6.80--
Intralipid 10% @ 388.20 ml @@
Energy content: 3.84 Kcal/g diet
Nitrogen content: 33.5 mg/g diet
# Energy content: 1.18 Kcal/g TPN solution
Nitrogen content: 10.08 mg/g TPN solution
The gravity of the TPN solution is 1.115 g/ml
* Table 2
** Table 3-1; Table 3-2
*** Table 4
Intralipid 10%, Clintec Nutrition Company, Deerfield,
IL, 60015
@@ Added to 2886 g TPN solution
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Table . Composition of t Amino Acid fixture in t
Amino Acid Diet and TP Solution
Formulation t
Amino acid (g/kg AAD),, Requirements
(g/2886g i
s rt .c ci .3
L-Asparagine 6.94 4.00
T r i 8.02 5.00
L i 10.50
L-Glutamic Acid 20.00 40.00
L-Glutamine 21.86 ®_
® r tin 
.2 4.00
L-Glyciine 
3.60 L-Alanine 
5.7
L-Cysteine 2 ---
L-ZT l i 12.78 6.00
ine 5.84
n
L-Methionine 5.00 6.00
Is ci 10.56 5.00
L-Leucine 16.94 7.50
- nin 19.80 8.00
L-Histi'dine 5.46 3.00
® i 15.02 7.00
L-Tryptophan 2.48 1.50
L-Arginine 7.02 6.00
r Nutrient Requirements Laboratory is , 3r .,
3
1978 National Academy of Sciences, Washington, D.C.
** Non-essential amino acids used to meet the total protein
requirement
* Converted to glutamic acid in vivo
Non-essential amino acids not required for the rat
Table B3-1. Mineral Compounds in the Amino Acid Diet and TPN
Solution
Mineral Formulation in Amino Formulation in
Acid Diet TPN Solution
Compound (mg/Kg AAD) (mg/2886g TPN)
d-Gluconic Acid
Hemicalcium salt 54,867.76 54,867.76
(CH 107 . 1/2Ca)
Potassium Phosphate
Monobasic; Anhydrous 13,923.27 13,923.27
(KH2PO4)
Sodium Phosphate
Monobasic;Monohydrate 3,688.56 3,688.56
(NaH2PO4 . H2 0)
Manganese Chloride
(MnCl 2 .4H 20) 180.11 180.11
Magnesium Sulfate
Anhydrous 1,980.19 1,980.19
(MgSO 4 )
Ferric Citrate
(FeC6 H5O7) 153.51 153.51
Cupric Sulfate
Pentahydrate 19.69 19.69
(CuSO 4 .5H 20)
Zinc Sulfate
(ZnSO 4 .7H 2 0) 52.87 52.87
Potassium Iodine
(KI) 0.20 0.20
Chromium
Potassium Sulfate 2.90 2.90
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p Dodecahydrate
1 r 4 2
Sodium nice
(2 e 3 0.22 0.22
Table B3-2. Mineral Elements in the in Acid Diet and TPN
titan
,n r 1 Formulation-- Formulation t
in AAD in TPN Requirement
Element (mg/Kg AAD) (mg/2886g TPN) (mg/Kg Diet)
Calcium 51000.00 51000.00
Potassium sk 41000.99 41000.99 31600.00
Phosphorus r rOOO.00 41000.00 41000.00
Sodium fir**# 614.80 614.80 500.00
Manganese 50.00 50.00 50.00
Chloride t 500.00 500.00
Magnesium 400.00 400.00 400.00
Ire 35.00 35.00 35.00
Copper 5.00 5.00 5.00
i 12.00 12.00 12.00
Chromium 0.30 0.30 0.30
Selenium 0.10 .1 .1
Iodine 
.1 0.15 0.15
Fluoride 
-- 1.00
Sulfur 535.94 535.94 300.00
rye t nt of- L or
3rd ed., 1978, National Academy of Sciences,
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Washington, D. C.
* Includes calcium in d-gluconic acid, calcium
pantothenate
** Includes potassium in potassium phosphate,
potassium iodine, chromium potassium sulfate
Includes phosphorus in potassium phosphate, sodium
phosphate
Includes sodium in sodium phosphate, sodium
selenite
Includes chloride in manganese chloride, choline
chloride, thiamin hydrochloride, pyridoxine
monohydrochloride
Includes sulfur in magnesium sulfate, cupric
sulfate, zinc sulfate, chromium potassium sulfate
Table B4. Vitamins in the Amino Acid Diet and TPN Solution
Rat Amino Acid TPN
Vitamin Requirement * Diet Solution
(mg/Kg Diet) (mg/Kg AAD) (mg/2886g TPN)
Thiamin
Hydrochloride 4.00 4.00 4.00
(C12H17ON4 ClSHCl)
d-Biotin 0.20 0.20
(C1 0H1 N2035)
Riboflavin 3.00 3.00 3.00
(C1 H20N40)
Niacin 20.00 20.00 20.00
Niacinamide
(C6H6N20)
Vitamin B6  6.00 6.00 6.00
Pyridoxine
Monohydrochloride
(CH11N 3 .Hcl)
Calcium Pantothenate 8.00 8.00 8.00
D-Pantothenic Acid
Hemicalcium Salt
(0C1f0. /2Ca)
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Folic Acid 1.00 1.00 1.00
Pteroylglutamic Acid
(C1 H 9N106)
Vitamin B12  0.05 0.05 0.05
Cyanocobalamin
(C 8 8CoN 4,4P)
Menadione 0.5 0.5
(C1 H8 02)
or
Phytonadione 0.05 -- 0.05 **
(C31H4602)
Choline
Chloride 1,000.00 1,695.79 1,695.79
([2-Hydroxye-
thyl] trimethyl-
ammonium)
(CH 4 ClNO)
Retinol
Acetate 1.376 1.376 2.752 ***
(C 22H320 2)
Cholecalciferol 0.025 0.025 0.020 ***
(C27H44 0)
DL-a-tocopheryl 30.00 30.00 -----
Acetate
(CH 5203)
DL-a-tocopherol 30.00 30.00 ****
(C29H)50
Not required for the rat
* Nutrient Requirement of Laboratory Animals, 3rd ed.,
1978, National Academy of Sciences,Washington, D. C.
** Present in 25 Al Aquamephyton, Merck Sharp & Dohme,
Div. of Merck & Co. Inc., West Point, PA 19486
*** Present in 80 Al Injacom 100, Roche Vitamins and Fine
Chemicals, a div. of Hoffmann-La Roche Inc., Nutley, NJ
07110
**** Present in 113.6 Ml Rocavit E, Roche Vitamins and Fine
Chemicals, a div. of Hoffmann-La Roche Inc., Nutley, NJ
07110. Also included is 1.6 mg DL--tocopherol in
Injacom 100, Roche Vitamins and Fine Chemicals, a div.
of Hoffmann-La Roche Inc., Nutley, NJ 07110
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Appendix C
C1. Preparation Amino 1 i
1. Weigh following vitamins and combine er
i i Hydrochloride
(x 12 1? 1 C1
d-Biotin 0.20 mg
1t? 16 2 3 I
Riboflavin 3.00
17 20 4 6
Niaciin 20.00 mg
Niacinamide
6 6 2
3. " 1 6 6.00 mg
Sri in
Monohydrochloride
8H11 3" Cl
Calcium
D-Pantothenic Acid
Hemicalcium Salt
(CqHj ,5. 1/2 Ca)
Folic Acid 1.00 mg
Pteroylglutamic Acid
1 1 7 6
Vitamin 12 0. 05 mg
Y
88 144 14
Menadione 0.5 mg
11 H802)
oll
Chloride 1,695.79
((2-Hydroxye-
thyl]trimethyl-
ammonium)
(C5H14ClNO)
Retinol
Acetate 1.376 mg
7
(C22H32o2)
Cholecalciferol 0.025 mg
(C27 44o)
DL-a-tocopheryl 30.00 mg
Acetate
(C31, 5203)
* Total weight of vitamin mixture, includes choline
chloride, for 1 kg diet is 1769.941 mg.
2. Weigh the following minerals and add to vitamin-cholin
mixture:
d-Gluconic Acid 54,867.76 mg
Hemicalcium salt
(C6H1 7 .1/2Ca)
Potassium Phosphate 13,923.27 mg
Monobasic; Anhydrous
(F312P04)
Sodium Phosphate 3,688.56 mg
Monobasic; Monohydrate
(NaH2PO4. H20)
Manganese Chloride 180.11 mg
(MnCl2.4H20)
Magnesium Sulfate 1,980.19 mg
Anhydrous
(MgS04)
Ferric Citrate 153.51 mg
(FeC6 H50 7)
Cupric Sulfate 19.69 mg
Pentahydrate
(CuS04.511)
Zinc Sulfate 52.87 mg
(ZnS04.7120)
Potassium Iodine 0.20 mg
(K(I)
Chromium 2.90 mg
Potassium Sulfate
Dodecahydrate
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r O2
Sodium el nit 0.22
(Na2SeO3)
Total weight of minerals for 1 diet i 74,869.28 .
Grind vitamins-mineral mixture thoroughly together and
set aside.
Weigh following amino acids n i together:
DL-Aspartic i 6.36 g
L-Asparagine 6.94 g
L-Threonine 8.02 g
L-Serine 10.50
L-Glutamic Acid 20.00 g
L-Glutamine 21.86 g
L-Proline 20.24 g
L-Glyciine 3.60 g
L-Alanine 5.76 g
L® i
L-Valine 12.78
DL-Methionine 5.84 g
L-Methionine 5.00 g
- c ci
L-Leucine 16.94 g
L-Phenylalanine 19.80 g
® i i i e 5.46 g
L-Lysine 15.02
L-Tryptophan 2.48 g
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L-Arginine 7.02 g
* Total weight of amino acids in 1 kg diet is 205 g.
5. Weigh 677.42 g dextrose and add it to vitamin-mineral
mixture.
6. Add amino acid mixture to vitamins-mineral-dextrose
mixture.
7. Weigh 34.20 g soybean oil and 6.80 g glycerin and add to
above mixture and mix thoroughly.
8. Keep diet refrigerated at 4 0 C. Lasts up to two weeks in
refrigerator.
81
C2. Procedure For Preparing 2588 al TPN Solution
- . Weigh following vitamins combine together-,
Thiamin Hydrochloride 4.00
12 17 4ClS Cl
d-Blotin 0.20 mg
o 1 203
Riboflavin 3.00 mg
I 46
Niacin 20.00 mg
icii
6
Vitamin 
rioi
0o r ri
c8 l l C3 ' l
Calcium Pantothenate 8.00 mg
D-Pantothenic Acid
Hemicalcium, Salt
(CgHlO,.1/2Ca)
Folic Acid 1.00 mg
royl u io of
1 1 7 6
Vitam 'in B,2 0.05 mg
y Canocobalamin
4 6 94 14
t Phytonadione 
0.05 mg
A 3'9 46 2
Choline
Chloride 1,695.79
([2-Hydroxye-
thyl]trimethyl-
ammonium)
C A4l
This vitamin mixture weighs (includes i chloride):
1738.09 .
2. Keep the above $ l separately.
2
3. Weigh the following minerals and mix together.
Potassium Phosphate 13,923.27 mg
Monobasic; Anhydrous
(KH 2P0 4)
Sodium Phosphate 3,688.56 mg
Monobasic; Monohydrate
(NaH2P0 4 .120)
Manganese Chloride 180.11 mg
(MnCl 2 . 4H20)
Magnesium Sulfate 1,980.19 mg
Anhydrous
(MgS04)
Cupric Sulfate 19.69 mg
Pentahydrate
(CuS04 .5H20)
Zinc Sulfate 52.87 mg
(ZnS0 4.720)
Potassium Iodine 0.20 mg
(KI)
Chromium 2.90 mg
Potassium Sulfate
Dodecahydrate
(CrK(0 4) 2)
Sodium Selenite 0.22 mg
(Na25e0 3)
* Total weight of this mineral mixture is 19,848.01 mg.
4. Keep the above mineral mixture separately.
5. Weigh the following amino acids and mix together:
DL-Aspartic Acid 6.36 g
L-Asparagine 6.94 g
L-Threonine 8.02 g
L-Serine 10.50 g
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L-Glutamic Acid 20.00 9
- lint ine 21.86 g
L-Proline 20.24
L-Glycine 3.60 g
L-Alanine 5.76 g
L-Cysteine
L-Valine 12.78 g
DL-Methionine 5.84 g
L-Methionine 5.00 g
- sol ci 10.56 g
L-Leucine 16.94 g
- i 19.80 g
L-Histidine 5.46 g
L-Lysine 15.02 g
L-Tryptophan 2.48 g
- r i i 7.02 g
Total weight this amino acid mixture is 205 .
Measure 1,600 i of I water into a 33,000 ml beaker.
7. Weigh 54,867.76 - uc i acid i with the
i i i xture. Add the i amno-gluconic ci i xture
the I water.
8. Heat the I water iixture on a hot plate while stirring
i th an automatic stirrer
mixing time to a minimum).
Dissolve 153.51 ferric citrate 'in 40 ml DDI water 'in
separate beaker. Heat the ferric citrate
(not exceeding 50 OC). col the tsolution when the
ferric citrate dissolves completely.
10. Add 777.42 g dextrose to the o- 1 is i
4
solution with the hot plate on "low" temperature. When
all nutrients are dissolved, cool solution to 22 WC.
11. Add all minerals, and then vitamins, to the solution on
the hot plate while stirring. Add DDI water to the
total volume of 2588 ml.
12. Filter solution to a sterile plastic container (Corning
Glass Works, Corning, NY): 600 ml/container.
13. Pipet 25 gl Aquamephyton (vitamin K) (Merck and Co.,
West Point, PA), to 2588 ml TPN solution.
14. Twenty-four hours before feeding, filter the TPN
solution into evacuation containers (Abbott
Laboratories, North Chicago, IL).
100 ml for two days
150 ml for three days
15. Store in refrigerator at 4 .C.
16. Immediately prior to infusion, add:
1). 388.20 ml Intraipid_10% (Clintec Nutrition Co.,
Deerfield, IL) to 2588 ml TPN solution.
(15 ml Intralipid/100 ml TPN )
2). 80 Ml Iniacom 100 (vitamin A & vitamin D)
(Hoffmann-La Roche, Nutley, NJ) to 2588 ml TPN
solution.
3). 113.6 Ml RocavitE (vitamin E) (Hoffmann-La Roche,
Nutley, NJ) to 2588 ml TPN solution.
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APPENDIX D
Zinc Analysis Procedure
Preparation and Digestion of Samples:
1. All glassware was soaked in a detergent solution
overnight and then rinsed with deionized water.
2. Detergent washed glassware was soaked in a 20% nitric
acid solution (made from 70% nitric acid and DDI water)
overnight. After rinsing with DDI water, the acid-
washed glassware was rinsed with 0.001 N EDTA solution
and then rinsed with DDI water.
3. Approximately 0.5 gram wet tissue samples were weighed
and transferred into a 50 ml Erlenmeyer flask. The
exception was weighing of the whole individual kidney,
testis, heart, and femur bone used for digestion. The
feces samples from the third collection (days 17-19 of
experiment) and sixth collection (days 26-28 of
experiment) were weighed and transferred into the
Erlenmeyer flask.
4. Two 0.5 gram bovine liver samples (SRM 1577b, NIST,
Gaithersburg, MD) were weighed for each tissue and feces
set (except femur bone and serum) and served as quality
controls. Two 0.5 gram samples of non-fat milk powder
(SRM 1549) were the designated controls for the femur
bone, and bovine serum (SRM 1598) was the control for
the serum samples. Two blanks, containing only
digestion reagents, were also prepared for each sample
set. Fifty-ml beakers were used to cover the Erlenmeyer
flasks containing the samples.
5. An entire set of tissue or feces was placed in muffle
furnaces randomly. Furnace temperature was increased
50*C/hour to 430 0 C and held at that temperature for 48
hours.
6. Samples were removed from the furnaces and cooled prior
to adding 0.10 ml of DDI water and 0.10 ml of 70% nitric
acid to each flask.
7, Hot plates were prepared in a laboratory hood, and
a set of sample tissue or feces was placed on them until
a temperature of 900C was reached. The samples were
then removed from the hot plates and cooled. After a
five-minute cooling, 0.5 ml of 50 % hydrogen peroxide
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was then added at 10 - 15 minute intervals. This cycle
was repeated four to five times with each sample set,
until all black carbon particles were digested.
8. After the last cycle, samples were evaporated to dryness
at 9000, cooled and 2.0 ml of DDI and 0.5 ml of 70 %
nitric acid were added to all flasks. Samples were
returned to the hot plates and heated at 9000 for 15
minutes to dissolve the residue.
9. After cooling, quantitative transfer of each sample was
completed to 5 ml volumetric flasks and adjusted to
volume with DDI water. Samples were then transferred to
polystyrene storage tubes washed with EDTA and
refrigerated at 40C.
10. The urine was prepared for digestion by addition of 20
Al of 36 % HCl. Two-ml samples of the urine were placed
in acid-washed borisilicate tubes and evaporated to
dryness in heating blocks at 9000. Then the digestion
protocol by Hill et al. (44) was followed, with a total
of 1.5 ml of Ultrex nitric acid added.
11. The urine samples were subject to the 15-minute heating
cycles at 9000 while adding 0.1 ml of 50 % hydrogen
peroxide per cycle. Samples were evaporated to dryness,
cooled, and DDI water and Hl were added. Samples were
reheated at 9000 for another 15 minutes, cooled, and
transferred quantitatively to a final volume of 2.5 to
5.0 ml with 0.1 1 Hl.
12. Sera were prepared for direct assay by AAS.
Analysis of Samples
13. A Perkin Elmer Flame Atomic Absorption Spectrophotometer
and Zn lamp analyzed the Zn concentration in the
samples. Acetylene gas and air were the fill and
oxidant for the flame.
14. Zinc standards (SRM 3168) were prepared in a 0.1 4 Hl
matrix at 0.25 ppm, 0.50 ppm, 1.00 ppm, 1.50 ppm, and
2.00 ppm concentrations. For serum, Zn standards were
prepared in a DDI water matrix at 0.25 ppm, 0.50 ppm,
and 0.75 ppm concentrations.
15. Samples were prepared for AAS aspiration by appropriate
dilution using an automatic diluter. Dilutions were
completed with 0.1 Hl (or with DDI water for the
serum). Standard reference materials were aspirated
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with their corresponding sample set. Bovine liver
standards were diluted 1:20 using 0.1 1 Hl. Milk
powder standards were diluted 1:10 using 0.1 4 HCl.
Bovine serum standards were diluted 1:5 with DDI.
16. Liver, small intestine, lung, heart, kidney, muscle and
corresponding blanks were aspirated after dilutions of
1:5 with 0.1 1 HCl. Serum and serum blanks were
aspirated after a 1:5 dilution with DDI, except two of
the samples which were diluted 1:10 with DDI. The
testicle and blanks were diluted 1:10 with 0.1 4 HCL and
the bone at 1:40. The feces and feces blanks were
diluted from 1:10 to 1:100 with 0.1 1 HCl.
17. The spectrophotometer was allowed stabilization time
after positioning the lamp, setting the resonant
wavelength, and igniting the flame. The parameters set
on the spectrophotometer were as follows:
ABS/CONC/E1: CONC AA/AA-BG/BG: AA
Energy: 58 Lamp MA: 15
Slit Height: 0.7 ) Peak: 213.9
Sample Aspirations: Triplicate
Aspiration Interval: 1.5 seconds
18. The instrument was brought to equilibrium with the 0.1 1
HCl solution and calibrated using the appropriate Zn
standard, prepared to cover the linear absorbance range
(0.25 ppm to 2.00 ppm) of Zn. This was usually
completed with the 1.00 ppm Zn standard (however,
calibration with 0.50 ppm Zn standard, in DDI, for
serum was used). A Zn standard was then aspirated to
ensure appropriate calibration.
19. Triplicate sample aspirations were then completed within
1.5 seconds and reading of the appropriate Zn standard
was completed every 5 to 10 samples to ensure the
spectrophotometer had not drifted from calibrated range.
20. If drift had occurred, the instrument was again brought
to equilibrium with the 0.1 M HCl solution, calibrated
if necessary, and the Zn standard was aspirated once
again to ensure appropriate calibration. The Zn
concentration reading of the samples was determined from
the mean concentration of the triplicate aspirations.
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1. Detergent: Versa-Clean Detergent, Fisher Scientific
Co., Pittsburgh, PA
2. EDTA: Fisher Certified, ACS, Fisher Scientific CO.,
Pittsburgh, PA
3. Nitric Acid: 70% Trace Metal Grade, Fisher Scientific
Co., Pittsburgh, PA
4. DDI Water: For washing and reagent preparation; MEGA-
PURE, Barnstead Co., Dubuque, IA
5. DDI Water: Added in samples during digestion, except in
urine and serum; Reagent Grade, Baxter
Healthcare Co., McGaw Park, IL
6. Hydrogen Peroxide: 50%, Certified, Stabilized; Fisher
Scientific Co., Pittsburgh, PA
7. Hydrogen Chloride: 36%, Sub-Boiling, Distilled, Sea-
Star Chemicals, Vancouver, British
Columbia, Canada
8. Ultrex Nitric Acid: 70%, Baker, Phillipsburg, NJ
9. DDI Water: For dilution of samples before analysis;
MIllipore Corp., Bedford, MA
10. Acetylene: For flame in AAS; Air Products and
Chemicals, Inc., Allentown, PA
Standard Materials:
1. Bovine Liver: Standard Reference Material 1577b,
National Institute of Standards and
Technology (NIST), Gaithersburg, MD
2. Non-fat Milk Powder: Standard Reference Material 1549,
NIST, Gaithersburg, MD
3, Bovine Serum Standard: Standard Reference Material
1598, NIST, Gaithersburg, MD
4, Zinc Standard: Standard Reference Material 3168,
NIST, Gaithersburg, MD
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1. Electronic Analytical Balance: Model A-250, Denver
Instrument Co., Arvado, Co
2. Muffle Furnaces: Type 4800 Furnace, Barnstead Co.,
Dubuque, IA
3. Hot Plate: Model p11, Corning Glass Works, Corning,
NY
4. Automatic Diluter: Micro Lab M, Hamilton Co., Reno, NV
5. AAS: Perkin Elmer Flame Atomic Absorption
Spectrophotometer, Model 5000, Perkin Elmer,
Norwalk, CT
6. Zn Lamp: Perkin Elmer, Norwalk, CT
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